How the prices of Pfizer and Moderna vaccines rise according to the Financial Times
Pfizer and Moderna have raised the prices of anti-Covid vaccines. All the numbers in the Financial Times article
The likely need for a third dose of the vaccine will be accompanied by a large outlay of public finances, higher than that already addressed.
Pfizer and Moderna prices rise
Pfizer and Moderna have raised the prices of their Covid vaccines that the states buy. To say it is the Financial Times that has examined the contracts stipulated between the pharmaceutical companies and the European Union. The new price for Pfizer vaccines is 19.50 euros against the 15.50 of the previous supply while that of Moderna has risen to 25.50 dollars per dose against 22.60 dollars of the previous agreement but less than the 28.50 dollars initially. expected after the order has been expanded.
The need for the third dose
The news of the upward retouching came as Europe, as well as the United States, is grappling with a surge in infections caused by the Delta variant which is also transmissible through vaccinated subjects. The new wave of cases is accompanied by the need to complete the vaccination campaign with a third dose . The forerunner of this new phase was Israel.
From the emergency to the market
The pharmaceutical companies had announced a rise in prices compared to those calmed in the first phase of the emergency . Basically, on the one hand, they had guaranteed initial access to the vaccine and then adapted to more purely market dynamics.
More effective mRNA vaccines
The mRNA vaccines have been shown to be more effective than the cheaper vaccines developed by Oxford / AstraZeneca and Johnson & Johnson. This allowed Pfizer and Moderna to renegotiate the terms of the agreements signed this year, for a total of 2.1 billion doses, and to push on the accelerator of the price. The price that the EU will pay with the new prices is around 41.5 billion euros compared to the more than 33.6 billion it would have spent at frozen prices.
Bourla: "Prices for rich countries comparable to middle-income ones"
Pfizer CEO Albert Bourla stressed the fairness of his company's pricing policy. Prices for higher-income countries would be "comparable," with middle-income countries paying about half, and low-income countries paying the costs.
Covax's bankruptcy
Sara Albiani , Oxfam Italia's policy advisor for global health, and Rossella Miccio , president of Emergency, are not of the same opinion, who have noted the substantial failure of the Covax initiative : in 2021 just 23% of the population of the countries in progress will be vaccinated. development. The initiative, which should allow developing countries access to vaccines, has paid for doses of Pfizer / BioNTech on average 5 times more than their potential production cost, struggling to have the necessary supplies quickly because the Richer countries were willing to pay higher prices. “ This is perhaps the most serious case of speculation in history – said Albiani and Miccio -. The huge resources that states are forced to pay by enriching CEOs and shareholders could be used to build new health facilities in poor countries, cut waiting lists for medical services, and guarantee dignified essential services ”.
The gap between traditional and mRNA vaccines will widen
As the Financial Times writes, according to forecasts by Airfinity, a life sciences consultancy commissioned by the British newspaper, the revenue gap between mRNA vaccines and more traditional rivals that contain viral proteins or an inactivated virus, it is set to expand further next year. According to these forecasts, sales of Pfizer serum will reach $ 56 billion , while Moderna will reach $ 30 billion , as they dominate high-income markets.
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/come-crescono-i-prezzi-di-pfizer-e-moderna-secondo-il-financial-times/ on Mon, 02 Aug 2021 14:28:12 +0000.